I think they will do some sort of deal with the new cash soon, and mgt will try and rev up optimism on the upcoming conference call (mgt has proven they know how to really hype this co.) , so we could see a brief lift. Still issues with this company that I would like to see taken care of - especially lack of solid and sustained revenue growth and profitability. Stock could go lower, but I will take my profits - for now.
I don't know what kind of hype/b.s. they are going to say on this conf call but their numbers should not be that great. They are a mostly cough and cold company.
The head lice product has not been launched yet, Cedax has not been stellar, no matter what they say, and medicaid gave them the boot. Really gave them the boot. No matter what their labeling says. The whole OTC monograph, but keep it behind the counter didn't work. Cooper's trick didn't work for long.
My guess is that they are going to take this money and put some new products in the reps bags and start working on the theobromine product. The two investment banks that bought up the stock (Aisling and Orbimed) would probably not have invested so much on just some products that 75 reps can sell.